Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Figure 1 Plasmatic neutrophil gelatinase associated lipocalin at baseline according to estimated glomerular filtration rate ranking. eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

Figure 2 Univariate linear correlations between plasmatic neutrophil gelatinase associated lipocalin (NGAL) at baseline and estimated glomerular filtration rate (A) and NGAL at baseline and age (B). Data are represented as a scatter plot in which each point represents a patient. Correlation coefficient, Pearson r values, and statistical significance are indicated. n = 48 patients. eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

Figure 3 Evolution of plasmatic neutrophil gelatinase associated lipocalin (A) and estimated glomerular filtration rate (B) during the first 12 wk of hepatitis C virus therapy with directly acting antiviral containing regimens. eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

Figure 4 Evolution of neutrophil gelatinase associated lipocalin (A) and estimated glomerular filtration rate (B) in 8 patients during the first 12 week of hepatitis C virus therapy with directly acting antiviral containing regimens. Number of patients and respective treatment for hepatitis C virus infection are specified. PEG-IFN: Pegylated-interferon; RBV: Ribavirin; TVR: Telaprevir, SMV: Simeprevir; DCV: Daclatasvir; eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.